In its place, the PBM included the Humira-referenced biosimilars Hyrimoz, Hadlima and adalimumab-fkjp (an unbranded product). Hyrimoz appears to be the most favored biosimilar. While removal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback